Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;3(2):217-24.
doi: 10.1016/j.coviro.2013.03.001. Epub 2013 Apr 4.

Intervention strategies for emerging viruses: use of antivirals

Yannick Debing  1 , Dirk Jochmans, Johan Neyts
Affiliations
Review

Intervention strategies for emerging viruses: use of antivirals

Yannick Debing et al. Curr Opin Virol. 2013 Apr.

Abstract

Today, small molecule antiviral drugs are available for the treatment of infections with herpesviruses, HIV, HBV and HCV as well as with influenza viruses. Ribavirin, a broad-spectrum (but aspecific) antiviral, has been approved for the treatment of infections with respiratory syncytial virus, HCV and Lassa virus. Yet, for many other viruses that cause life-threatening infections [most of which are considered emerging and/or neglected] there are no drugs available. Ideally, potent and broad-spectrum (i.e., pan-genus or pan-family virus activity) antiviral drugs should be developed whereby one drug could be used for the treatment of a number of such viral infections. We here review recent evolutions in the search for inhibitors of emerging and neglected RNA viruses.

PubMed Disclaimer

References

    1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed

    2. Characterization of the novel coronavirus-EMC.

    1. World Health Organization . WHO Press; 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control — New Edition. - PubMed
    1. Simmons C.P., Wolbers M., Nguyen M.N., Whitehorn J., Shi P.Y., Young P., Petric R., Nguyen V.V., Farrar J., Wills B. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis. 2012;6:e1752. - PMC - PubMed

    2. An excellent review on treatment of dengue and useful recommendations for future clinical development.

    1. Julander J.G. Experimental therapies for yellow fever. Antiviral Res. 2013;97:169–179. - PMC - PubMed
    1. Delang L., Coelmont L., Neyts J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses. 2010;2:826–866. - PMC - PubMed

Publication types

MeSH terms

Substances